DontLose
$ELN Bapi Alz drug passes +50%, fails - 10%. Tysabri treatment no brainer for MS patients leaving ABCR treatment. 2 year price target = 25$.
- About
- Help
- Blog
- Jobs
- Press
- Tools
- Mobile
- Developers
- House Rules
- For Public Companies
- For Market Professionals
-
- Terms
- Privacy
- Disclaimer
- Market Quotes provided by Xignite © 2013 StockTwits, Inc.